Pharma BD Deal Intelligence

Akari Therapeutics Plc / Whitehawk Therapeutics, Inc.

2026 · Co-Development · Complete

Akari Therapeutics and Whitehawk Therapeutics entered a strategic preclinical research collaboration to evaluate combining Akari's PH1 spliceosome-modulating payload with Whitehawk's topoisomerase I inhibitor ADC platform to assess dual-payload compatibility and synergy. Akari leads design, execution and evaluation of the research; financial terms were not disclosed and no commercial rights were granted.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals